Compare Adaptive Biotechnologies Corp (ADPT) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Kingsoft Cloud Holdings Limited — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Kingsoft Cloud Holdings Limited trades at $11.67 (market cap $3.53B). The key difference: Adaptive Biotechnologies Corp and Kingsoft Cloud Holdings Limited are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| ADPT | KC | |
|---|---|---|
Market Cap | $4.04B | $3.53B |
Sector | Health | Technology |
52-Week High | $25.45 | $18.21 |
52-Week Low | $12.30 | $8.58 |
Enterprise Value | $4.10B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Kingsoft Cloud (KC) trades at $11.67, down 2.42% today, amid a bullish technical signal with strong analyst support. The company shows robust revenue growth, with Q1 2026 sales up 37% year-over-year, but remains unprofitable with a net margin of -9.39%. Recent news highlights AI-driven growth, with AI cloud billing now surpassing half of public cloud revenue, fueling positive sentiment.
KC presents a high-risk, high-reward opportunity. The bullish analyst consensus (70% buy ratings) and AI expansion offer significant upside potential, but persistent losses, high debt, and China regulatory risks pose substantial threats. Profitability improvement is critical for sustaining investor confidence and justifying current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
